Nova Patents
EP4241784A3

Artificial nucleic acid molecules for improved protein expression

Abstract

The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3'-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

Term

9.2 yearsto projected expiry

Projected expiry 11 December 2035, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

Every citation, both ways

Citations
DocumentRelationOfficeCited during
WO0107590A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO02098443A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO2005075644A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO2007036366A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO2007068265A1CitesWorld Intellectual Property Organization (WIPO)Search report
WO2008112127A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO2013120629A1CitesWorld Intellectual Property Organization (WIPO)Search report
WO2013143698A1CitesWorld Intellectual Property Organization (WIPO)Search report
WO2013143699A1CitesWorld Intellectual Property Organization (WIPO)Search report
WO2013143700A2CitesWorld Intellectual Property Organization (WIPO)Search report
WO2015101415A1CitesWorld Intellectual Property Organization (WIPO)Search report
WO2016005324A1CitesWorld Intellectual Property Organization (WIPO)Search report
EP3594337A1CitesEuropean Patent Office (EPO)Search report
S. HOLTKAMP ET AL: "Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells", BLOOD, vol. 108, no. 13, 15 December 2006 (2006-12-15), pages 4009 - 4017, XP055044965, ISSN: 0006-4971, DOI: 10.1182/blood-2006-04-015024Non-patent–Search report
LEDDA M ET AL: "Effect of 3'UTR length on the translational regulation of 5'-terminal oligopyrimidine mRNAs", GENE, ELSEVIER, AMSTERDAM, NL, vol. 344, 3 January 2005 (2005-01-03), pages 213 - 220, XP027872598, ISSN: 0378-1119, [retrieved on 20050103]Non-patent–Search report
"Homo sapiens RPL36AL mRNA for ribosomal protein L36a-like, complete cds", EMBL, 2 October 2002 (2002-10-02), XP002699423Non-patent–Search report